Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$75.41 - $84.21 $90,492 - $101,051
1,200 Added 26.09%
5,800 $460,000
Q2 2024

Aug 15, 2024

BUY
$68.26 - $76.19 $13,652 - $15,238
200 Added 4.55%
4,600 $350,000
Q1 2024

May 07, 2024

BUY
$67.36 - $77.59 $296,384 - $341,396
4,400 New
4,400 $322,000
Q3 2023

Nov 14, 2023

BUY
$61.9 - $72.77 $662,330 - $778,639
10,700 New
10,700 $715,000
Q3 2021

Nov 15, 2021

SELL
$60.19 - $75.29 $890,812 - $1.11 Million
-14,800 Reduced 80.0%
3,700 $241,000
Q2 2021

Aug 11, 2021

BUY
$62.12 - $74.2 $832,408 - $994,280
13,400 Added 262.75%
18,500 $1.36 Million
Q4 2020

Feb 16, 2021

SELL
$62.61 - $71.29 $262,962 - $299,418
-4,200 Reduced 45.16%
5,100 $364,000
Q3 2020

Nov 16, 2020

BUY
$51.39 - $72.41 $20,556 - $28,964
400 Added 4.49%
9,300 $647,000
Q2 2020

Aug 14, 2020

SELL
$39.55 - $54.65 $118,649 - $163,950
-3,000 Reduced 25.21%
8,900 $472,000
Q1 2020

May 15, 2020

BUY
$34.75 - $45.85 $218,925 - $288,855
6,300 Added 112.5%
11,900 $480,000
Q4 2019

Feb 14, 2020

SELL
$36.66 - $41.78 $175,967 - $200,544
-4,800 Reduced 46.15%
5,600 $227,000
Q3 2019

Nov 14, 2019

BUY
$34.82 - $39.26 $66,158 - $74,594
1,900 Added 22.35%
10,400 $394,000
Q1 2019

May 15, 2019

SELL
$35.77 - $40.57 $218,197 - $247,477
-6,100 Reduced 41.78%
8,500 $344,000
Q4 2018

Feb 14, 2019

SELL
$31.89 - $38.44 $114,804 - $138,384
-3,600 Reduced 19.78%
14,600 $550,000
Q3 2018

Nov 14, 2018

BUY
$29.25 - $36.73 $204,750 - $257,109
7,000 Added 62.5%
18,200 $630,000
Q2 2018

Aug 14, 2018

BUY
$28.49 - $35.06 $319,088 - $392,672
11,200 New
11,200 $361,000

Others Institutions Holding RDY

About DR REDDYS LABORATORIES LTD


  • Ticker RDY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 166,028,992
  • Market Cap $2.55B
  • Description
  • Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-t...
More about RDY
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.